

Supplementary Table 5. Description of bisphosphonates treatment after stopping denosumab

Sex/Age	BPs drug	Time from last DMAb to BPs (months)	Spine fractures	Time from last DMAb to spine fracture (months)	HyperCa	Time from last DMAb to hyperCa (months)	Follow-up (from last DMAb to last visit) (months)
F/57	Zoledronate 4 mg	20	No	-	Yes (cancer-related)	18	22
F/65	Zoledronate 4 mg	17	Yes (T3, T10, L1) (DMAb-related)	16	No	-	24
F/69	Zoledronate 4 mg	2	No	-	No	-	67
M/70	Zoledronate 4 mg	0	No	-	No	-	7

BPs, bisphosphonates; DMAb, denosumab; hyperCa, hypercalcemia; F, female; M, male.